Navigation Links
R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
Date:10/24/2007

ges in hematologic or other laboratory parameters.

Part 3 is a multi-center, observer-blinded, within-cohort randomized, placebo-controlled study being conducted in up to 75 treatment-naive patients with genotype 1 hepatitis C virus. The primary objective is to assess the safety, tolerability and pharmacokinetics of R7128 in combination with Pegasys plus Copegus. The secondary objective of Part 3 is to evaluate the short-term change in HCV RNA. The study will include two to three oral doses of R7128 (500 mg to 1500 mg) that are being administered twice-daily with Pegasys plus Copegus for 28 days.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that the FDA withdraws the R7128 fast track designation, the risk that the FDA does not expedite the review or approval of any application for R7128, the risk that adverse events could cause the cessation of the Phase 1 study and/or our development of R7128, the risk that our collaboration with Roche will not continue or
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
5. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
8. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
9. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
10. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
11. Point of Care Strep Tests Speed Treatment, Lower Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... CARPINTERIA, Calif. , Sept. 2, 2014 ... assessments and penetration testing services, today released an IT ... industry. "Today,s healthcare CEOs are presiding over ... industry," said Daniel W. Berger , Redspin,s President ... help CEO,s and their Boards of Directors understand why ...
(Date:9/2/2014)... BEIJING , Sept. 2, 2014  Sinovac Biotech Ltd. ... products in China , today announced that ... in September: , Morgan Stanley Global Healthcare Conference, ... September 9 and 10, 2014. , Morgan Stanley Asia ... Hotel on September 11, 2014. , Aegis Healthcare & ...
(Date:9/2/2014)... Sept. 2, 2014  Drug delivery technologies that improve ... part of the entire drug development process. Pharmaceutical ... new vaccine delivery technologies in a bid to ... delivery procedures. New analysis from Frost ... the needle-free delivery sector currently makes up a ...
Breaking Medicine Technology:Sinovac to Participate in Upcoming Investor Conferences 2Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 2Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 3
(Date:9/2/2014)... (PRWEB) September 02, 2014 MyRounding, the ... care, has been selected from a group of over ... the 2014 PrIME Digital Health Challenge. The competition will ... another, Tuesday, Sept. 9th at the CSU Denver Atrium ... MyRounding is based in Denver, Colo. The cloud-based, SaaS ...
(Date:9/2/2014)... BESLER Consulting, a leading provider of Medicare ... to announce that it has released a special report ... 2015 Hospital Inpatient Prospective Payment System (IPPS) final rule ... Services. , “Hospitals are facing decreased Medicare reimbursements in ... BESLER’s President and Chief Executive Officer. “We are happy ...
(Date:9/2/2014)... September 02, 2014 “Is there an ... question that millions of people ask. Diagnosing and curing ... patients and their families or treatment partners. The diagnostic ... its distinct similarities to other skin conditions such as: ... bites, eczema, varicella and many others. Scabies is ...
(Date:9/2/2014)... 02, 2014 Michigan’s health care landscape ... Act and the Healthy Michigan Plan. Throughout these changes, ... a trusted funding resource for under-served individuals. Federal and ... or underinsured women between the ages of 50 and ... percent of the federal poverty level. , ...
(Date:9/2/2014)... Recently, Os-Monitor.com, an innovative company that provides many kinds ... employee internet monitoring products ( http://www.os-monitor.com ). Furthermore, the ... 10% off, on these useful items. , True ... different kinds of high end monitoring programs on its ... of all sizes. With its high end programs, the ...
Breaking Medicine News(10 mins):Health News:MyRounding Selected for Digital Health Venture Showcase Finals Top Three Startups Awarded $50,000 2Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 2Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 3Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 4Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 2Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 3Health News:Useful Employee Internet Monitoring Products Now For Sale At Os-Monitor.com 2
... (sildenafil) can improve exercise capacity and functional ability in ... high pressure in the blood vessels that enter the ... report by Reuters, the findings, which appear in The ... study of 278 patients who were randomly selected to ...
... to stress during early life can lead to an ... adolescence.// It therefore, highlights the need for a counseling ... of growth. ,Several studies have established a ... with an increased risk of developing attachment disorders. These ...
... Death Syndrome (SIDS) has found out that nearly all cases ... a male sex hormone. //The levels are considerably higher in ... who have died suddenly from other causes. ,Researchers ... collected from 169 infants who had died of SIDS and ...
... findings were published by chemists at Harvard University, who ... they trigger could hold the key to oncogenesis,// the ... arises when an oncoprotien, a protein known to cause ... development of cancer, 'We present the hypothesis that an ...
... Research Institute have now found out that heart disease ... the thyroid gland.// Aggressive treatment of hypothyroidism and borderline ... diseases to a significant extent. ,The study has ... can be extrapolated to human beings as well. The ...
... of the National Cancer Institute conducted a meta-analysis of ... and the prevalence and associated mortality from colorectal cancer. ... of the Karolinska Institute in Stockholm, and colleagues. The ... at a 30 percent risk of developing colorectal cancer ...
Cached Medicine News:Health News:Teenage Mental Problems Could Be The Result Of Stress During Early Life 2Health News:Proper Treatment of Hypothyroidism Found To Prevent Heart Diseases 2
The Buckle Apron has a 2" wide belt with a rugged side-release buck. The belt and buckle are adjustable to provide a snug and comfortable fit while still offering .50mm Pb protection....
Setting a new standard in protective apparel. The unique, patented Cool-Tech™ mesh-back design fits the natural contour of the body while reducing the amount of weight carried on the shoulders ...
Apron,special Proceddure...
Crisscross shoulder design facilitates better posture and distributes weight to back and hips for greater comfort. Shoulder pads soften shoulder contact with apron for additional comfort....
Medicine Products: